Candel therapeutics reports third quarter 2021 financial results and recent corporate highlights

Needham, mass., nov. 12, 2021 (globe newswire) -- candel therapeutics, inc. (“candel” or “the company”) (nasdaq: cadl), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today reported financial results for the third quarter ended september 30, 2021 and provided a corporate update.
CADL Ratings Summary
CADL Quant Ranking